BaseLaunch selects Umlaut.bio for support thereby raising the pre-seed funding to a total of ~EUR 3m Prof. Dr. Oliver Distler, Universitätspital Zurich,  joins Umlaut.bio’s SAB catalyzing the development of the systemic sclerosis franchise Prof. Dr. Tsutomu Suzuki, University Tokio, completes the SAB, underpinning the worldwide leadership in tRNA science

NewBiologix S.A., a biotechnology company advancing recombinant adeno-associated virus (rAAV) production through next-generation clonal HEK293 cell line technology, today announced publication of peer-reviewed data in Biotechnology Reports (Vol. 49, March 2026). Paper reports two-fold higher full-to-empty rAAV ratio using NBX1P01 compared to a leading commercial HEK293 cell line.

Partnership will deliver AI-guided end-to-end workflow to access challenging membrane protein targets To de-risk and shorten path to critical structural and biophysical insights that inform structure-based drug design

InSphero AG, the global market leader in 3D cell-based assays and organ-on-chip systems signed a partnership with PharmaNest Inc, a Princeton, NJ-based digital pathology company.

A new united voice for a strategic sector for Europe

Akceso Advisors AG, a leading independent global advisory firm specializing in market access, pricing, reimbursement strategy, operations and policy-setting for life-science companies and authorities, announced today the election of Dr. Seng Chin Mah as a new non-executive member of its Board of Directors.